

(Company No : 680889-W)

SUNZEN BIOTECH BERHAD
(Incorporated in Malaysia)

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
FOR THE FINANCIAL PERIOD ENDED 30 JUNE 2012**

	Current Quarter Ended 30.6.2012 (Unaudited) RM'000	Corresponding Quarter Ended 30.6.2011 (Unaudited) RM'000	Current Year-To-Date Ended 30.6.2012 (Unaudited) RM'000	Corresponding Year-To-Date Ended 30.6.2011 (Unaudited) RM'000
Revenue	7,947	7,891	16,100	15,446
Operating profit	2,583	2,781	5,168	5,515
Operating expenses	(2,107)	(2,097)	(3,994)	(3,927)
Finance costs	(113)	(121)	(221)	(233)
Profit before taxation	363	563	953	1,355
Tax expense	(123)	(148)	(294)	(316)
Profit after taxation	240	415	659	1,039
Other comprehensive income, net of tax	4	6	6	5
Total comprehensive income	244	421	665	1,044
Profit after taxation attributable to Owners of the Company:	240	415	659	1,039
Total comprehensive income attributable to Owners of the Company:	244	421	665	1,044
Earnings per share (sen) attributable to Owners of the Company: - Basic	0.16	0.28	0.44	0.70

Note:-

The above condensed consolidated statements of comprehensive income should be read in conjunction with the audited financial statements for the financial year ended 31 December 2011 and the accompanying explanatory notes attached to the interim financial statements.

SUNZEN BIOTECH BERHAD

(Incorporated in Malaysia)

**CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
AS AT 30 JUNE 2012**

	As At Current Year Quarter 30.6.2012 (Unaudited) RM'000	As At Financial Year End 31.12.2011 (Audited) RM'000
ASSETS		
Non - current assets		
Property, plant and equipment	16,681	16,276
Product development expenditure	637	760
Goodwill	58	58
Quoted investments	-	5
	<u>17,376</u>	<u>17,099</u>
Current assets		
Inventories	10,375	9,557
Trade receivables	6,466	6,390
Other receivables, deposits and prepayments	464	730
Tax refundable	85	194
Fixed and short term deposits with licensed banks	3,336	3,289
Cash and bank balances with licensed banks and other financial institution	6,376	7,086
	<u>27,102</u>	<u>27,246</u>
TOTAL ASSETS	<u>44,478</u>	<u>44,345</u>
EQUITY AND LIABILITIES		
Equity		
Share capital	14,939	14,939
Share premium	3,520	3,520
Retained profits	16,964	16,305
Fair value reserve	-	*
Revaluation reserves	3,178	3,178
Merger deficit	(8,397)	(8,397)
Currency translation reserve	(23)	(29)
	<u>30,181</u>	<u>29,516</u>
Non-current liabilities		
Deferred taxation	611	580
Hire purchase payables	148	218
Term loans	5,115	5,377
	<u>5,874</u>	<u>6,175</u>
Current Liabilities		
Trade payables	3,844	3,311
Bill payable	1,971	3,101
Other payables and accruals	1,955	1,575
Amount owing to directors	1	2
Hire purchase payables	139	135
Term loans	513	499
Provision for taxation	-	31
	<u>8,423</u>	<u>8,654</u>
TOTAL LIABILITIES	<u>14,297</u>	<u>14,829</u>
TOTAL EQUITY AND LIABILITIES	<u>44,478</u>	<u>44,345</u>
Net assets per share (RM) attributable to owners of the Company	<u>0.20</u>	<u>0.20</u>

Note:-

* RM650

The above condensed consolidated statements of financial position should be read in conjunction with the audited financial statements for the financial year ended 31 December 2011 and the accompanying explanatory notes attached to the interim financial statements.

The net assets per share attributable to owners of the Company is calculated based on net assets value and the issued paid up share capital of 149,390,500 shares.

(Company No : 680889-W)

SUNZEN BIOTECH BERHAD

(Incorporated in Malaysia)

**CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
FOR THE FINANCIAL PERIOD ENDED 30 JUNE 2012**

			Non-distributable		Merger Deficit RM'000	Currency Translation Reserve RM'000	Distributable Retained Profits RM'000	Total Equity RM'000
	Share Capital RM'000	Share Premium RM'000	Fair Value Reserve RM'000	Revaluation Reserves RM'000				
<u>6 months ended 30 June 2012</u>								
(Unaudited)								
Balance at 1 January 2012	14,939	3,520	*	3,178	(8,397)	(29)	16,305	29,516
Total comprehensive income for the financial period	-	-	**	-	-	6	659	665
Balance at 30 June 2012	14,939	3,520	-	3,178	(8,397)	(23)	16,964	30,181
<u>6 months ended 30 June 2011</u>								
(Unaudited)								
Balance at 1 January 2011	14,939	3,520	5	3,179	(8,397)	-	15,219	28,465
Total comprehensive income for the financial period	-	-	5	-	-	-	1,039	1,044
Tax-exempt dividend	-	-	-	-	-	-	(672)	(672)
Balance at 30 June 2011	14,939	3,520	10	3,179	(8,397)	-	15,586	28,837

Note:-

- * RM650
- ** (RM650)

The above condensed consolidated statements of changes in equity should be read in conjunction with the audited financial statements for the financial year ended 31 December 2011 and the accompanying explanatory notes attached to the interim financial statements.

(Company No : 680889-W)

SUNZEN BIOTECH BERHAD

(Incorporated in Malaysia)

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE FINANCIAL PERIOD ENDED 30 JUNE 2012**

	Current Year To Date Ended 30.6.2012 (Unaudited) RM'000	Corresponding Year To Date Ended 30.6.2011 (Unaudited) RM'000
Cash flows from/(for) operating activities		
Profit before taxation	953	1,355
Adjustments for:-		
Depreciation of property, plant and equipment	309	251
Non-cash items	376	508
Operating profit before working capital changes	<u>1,638</u>	<u>2,114</u>
Changes in working capital	<u>(934)</u>	<u>(909)</u>
	704	1,205
Net tax paid	(185)	(223)
Interest paid	(213)	(212)
Net cash from operating activities	<u>306</u>	<u>770</u>
Cash flows from/(for) investing activities		
Interest received	48	68
Purchase of property, plant and equipment	(717)	(342)
Proceeds from disposal of quoted investment	6	-
Net cash for investing activities	<u>(663)</u>	<u>(274)</u>
Cash flows from/(for) financing activities		
Drawdown of term loans	-	665
Repayment of term loans	(245)	(148)
Repayment to directors	(1)	(76)
Repayment of hire purchase obligations	(66)	(43)
Payment of dividend	-	(896)
Net cash for financing activities	<u>(312)</u>	<u>(498)</u>
Net decrease in cash and cash equivalents	(669)	(2)
Cash and cash equivalents at beginning of the financial period	10,375	11,400
Foreign exchange difference	6	-
Cash and cash equivalents at end of the financial period	<u>9,712</u>	<u>11,398</u>
Cash and cash equivalents comprise:		
Fixed and short term deposits with licensed banks	3,336	5,694
Cash and bank balances with licensed banks and other financial institution	6,376	5,704
	<u>9,712</u>	<u>11,398</u>

Note:-

The above condensed consolidated statements of cash flows should be read in conjunction with the audited financial statements for the financial year ended 31 December 2011 and the accompanying explanatory notes attached to the interim financial statements.